In last trading session, ITeos Therapeutics Inc (NASDAQ:ITOS) saw 0.37 million shares changing hands with its beta currently measuring 1.40. Company’s recent per share price level of $9.27 trading at $0.09 or 0.98% at ring of the bell on the day assigns it a market valuation of $338.56M. That closing price of ITOS’s stock is at a discount of -102.27% from its 52-week high price of $18.75 and is indicating a premium of 9.28% from its 52-week low price of $8.41. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.56 million shares which gives us an average trading volume of 660.65K if we extend that period to 3-months.

For ITeos Therapeutics Inc (ITOS), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 1 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 1 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.89 in the current quarter.

ITeos Therapeutics Inc (NASDAQ:ITOS) trade information

Upright in the green during last session for gaining 0.98%, in the last five days ITOS remained trading in the green while hitting it’s week-highest on Wednesday, 11/06/24 when the stock touched $9.27 price level, adding 3.84% to its value on the day. ITeos Therapeutics Inc’s shares saw a change of -15.34% in year-to-date performance and have moved 5.22% in past 5-day. ITeos Therapeutics Inc (NASDAQ:ITOS) showed a performance of 2.21% in past 30-days. Number of shares sold short was 3.82 million shares which calculate 4.31 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of 36 to the stock, which implies a rise of 74.25% to its current value. Analysts have been projecting 31 as a low price target for the stock while placing it at a high target of 46. It follows that stock’s current price would drop -234.41% in reaching the projected high whereas dropping to the targeted low would mean a loss of -234.41% for stock’s current value.

ITeos Therapeutics Inc (ITOS) estimates and forecasts

Statistics highlight that ITeos Therapeutics Inc is scoring comparatively lower than the scores of other players of the relevant industry. The company lost -46.85% of value to its shares in past 6 months, showing an annual growth rate of -15.56% while that of industry is 16.60. Apart from that, the company came lowering its revenue forecast for fiscal year 2024. This year revenue growth is estimated to rise 263.90% from the last financial year’s standing.

6 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 16.67M for the same.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -40.62% during past 5 years.

ITeos Therapeutics Inc (NASDAQ:ITOS)’s Major holders

Insiders are in possession of 0.70% of company’s total shares while institution are holding 110.32 percent of that, with stock having share float percentage of 111.10%. Investors also watch the number of corporate investors in a company very closely, which is 110.32% institutions for ITeos Therapeutics Inc that are currently holding shares of the company. BLACKROCK INC. is the top institutional holder at ITOS for having 3.73 million shares of worth $55.37 million. And as of 2024-06-30, it was holding 10.4094 of the company’s outstanding shares.

The second largest institutional holder is RA CAPITAL MANAGEMENT, L.P., which was holding about 3.52 million shares on 2024-06-30. The number of shares represents firm’s hold over 9.8129 of outstanding shares, having a total worth of $52.2 million.